Bristol-Myers won't seek accelerated Opdivo lung cancer approval
January 19, 2017 at 18:49 PM EST
Jan 19 (Reuters) - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer.
